New FDA priority review vouchers go to Lilly, Novo, Vertex
WASHINGTON — The Food and Drug Administration on Thursday announced the second batch of companies being granted a “Commissioner’s…
SAMHSA cuts endanger people facing addiction or mental illness
O. Rose Broderick reports on the health policies and technologies that govern people with disabilities’ lives. Before coming…
Launch prices for new drugs ‘significantly’ exceed inflation, analysis says
Amid intensifying angst over prescription drug prices, a new analysis found that the median net price for 154…
FDA approved fewer drugs in third quarter, analysis finds
The upheaval at the Food and Drug Administration appears to be taking a toll on the pharmaceutical industry,…
Lyra Health launches ‘clinical-grade’ mental health chatbot
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
Startup tech helps Parkinson’s disease patients track symptoms
Mario Aguilar covers technology in health care, including artificial intelligence, virtual reality, wearable devices, telehealth, and digital therapeutics.…
Parents flock to Tylenol alternatives amid Trump autism claims
When President Trump warned that pregnant women and children should avoid taking Tylenol, the wellness industry was ready…
Telehealth growth fueled by doctors with 50 state licenses
Jonah Mink started racking up medical licenses during the Covid-19 pandemic. The family medicine doctor, who finished his…
Tylenol’s 70-year history: From kids’ drug to political controversy
Megan Molteni reports on discoveries from the frontiers of genomic medicine, neuroscience, and reproductive tech. She joined STAT…
Acadia Pharmaceuticals drug for rare genetic condition fails late-stage study
Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall…
FDA cracks down on prescription drug ads but lacks staff
WASHINGTON – In an unprecedented move, federal regulators published about 100 warning letters sent to pharmaceutical companies and health…
Let the rulemaking begin: Why direct-to-consumer drug ads deserve a closer look
Call it death by disclosure. After nearly 30 years in which prescription drug ads have become a fixture…